Abstracts tagged "antigen RA"

Abstract Number: 2900 • 2018 ACR/ARHP Annual Meeting
Impaired TCR Signaling Paves the Way for Cytokine Hyper-Responsiveness in Arthritogenic T Cells
Judith Ashouri¹, Lih-Yun Hsu¹, Dmitry Rychkov², Marina Sirota², Lisa Lattanza³, Eric Hansen³, Julie Zikherman¹ and Arthur Weiss¹, ¹Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA, ³Orthopedic Surgery, University of California, San Francisco, San Francisco, CA
Background/Purpose: The inability to identify relevant arthritogenic CD4 T cells in patients and in murine disease models has limited our understanding of disease initiating events…
Abstract Number: 834 • 2017 ACR/ARHP Annual Meeting
Citrulline-Polyspecific B Cell Antigen Receptors Arising from Somatic Hypermutation within Clades Demonstrate Pathogenicity in Rheumatoid Arthritis
Philip J. Titcombe^1,2, Gustaf Wigerblad³, Natalie Sippl³, Na Zhang¹, Anna K. Shmagel⁴, Peter Sahlström⁵, Yue Jack Zhang¹, Laura Barsness Motschenbacher¹, Yogita Ghodke-Puranik⁶, Monika Hansson⁷, Lena Israelsson⁵, Timothy B. Niewold⁸, Lars Klareskog⁹, Camilla Svensson¹⁰, Khaled Amara⁷, Vivianne Malmström¹¹ and Daniel L. Mueller¹, ¹Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, ²Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatic & Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, ⁵Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁶Colton Center for Autoimmunity, New York University, New York, NY, ⁷Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁸Rheumatology and Immunology, Mayo Clinic, Rochester, MN, ⁹Rheumatology unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ¹⁰Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, ¹¹Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Citrulline–modified proteins arising from the post-translational modification of arginine residues are recognized as primary rheumatoid arthritis (RA) autoantigen targets based on the strong association…
Abstract Number: 951 • 2017 ACR/ARHP Annual Meeting
Cross Sectional Analysis of Citrullinated-Synovial Antigen-Specific CD4+ T Cells in an RA Cohort Demonstrates Antigen Based Differences in T Cell Frequency, Phenotype and the Influence of Immunotherapy
Cliff Rims¹, Sylvia Posso¹, Bernard Ng², Jeffrey Carlin³, Eddie James⁴ and Jane H. Buckner⁴, ¹Translational Research, Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Rheumatology, VA Puget Sound Healthcare System, Seattle, WA, ³Rheumatology, Virginia Mason Medical Center, Seattle, WA, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: The presence of ACPA in RA indicates that an immune response directed toward citrullinated synovial antigens participates in disease development or persistence. Research from…
Abstract Number: 3022 • 2016 ACR/ARHP Annual Meeting
Autoantibodies to Peptidylarginine Deiminase 2 Protect Against Radiographic Progression in Patients with Rheumatoid Arthritis
Erika Darrah¹, Jon T. Giles², Ryan Davis¹, Pooja Naik¹, Maximilian Konig¹ and Felipe Andrade¹, ¹Department of Medicine, Division of Rheumatology, The Johns Hopkins University, Division of Rheumatology, Baltimore, MD, ²Columbia University, College of Physicians and Surgeons, Division of Rheumatology, New York, NY
Background/Purpose: The mechanisms that drive clinical heterogeneity and outcomes in patients with rheumatoid arthritis (RA) are poorly understood, but precise biomarkers may identify clinically unique…
Abstract Number: 1946 • 2015 ACR/ARHP Annual Meeting
A Novel HLA-DRB1*10:01 Restricted T Cell Epitope from Citrullinated Type II Collagen Relevant for Rheumatoid Arthritis
Karine Chemin¹, Sabrina Pollastro², Eddie James³, Changrong Ge⁴, Inka Albrecht⁵, Jessica Herrath⁶, Christina Gerstner⁷, Thais Rizzi², Karolina Tandre⁸, Lars Rönnblom⁸, Anca I Catrina⁹, Rikard Holmdahl¹⁰, L. Klareskog¹¹, Niek De Vries¹² and Vivianne Malmström¹¹, ¹Medicine, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Department of Clinical Immunology and Rheumatology, Amsterdam, Netherlands, ³Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁴Department of Medical Biochemistry and Biophysics, Medical Inflammation Research, Karolinska Institute, Stockholm, Sweden, ⁵Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁶Department of Medicine,, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁷Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Solna, Stockholm, Sweden, ⁸Section of Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁹Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ¹⁰Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, ¹¹Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ¹²Dept. of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Antibodies against citrullinated collagen type II (Cit-CII) are common in sera and synovial fluids of Rheumatoid Arthritis (RA) patients, whereas the known CII T-cell…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].